| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine [G. W. K., S. J. H., C. P. O.] and Microbiology/Immunology [G. W. K.], Medical College of Virginia, and McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249
At least 70% of small cell lung cancer (SCLC) tumors and tumor-derived cell lines coexpress the genes for stem cell factor (SCF) and its receptor, the c-kit proto-oncogene. To assess the impact of coexpression of the growth factor and receptor on SCLC growth, the NCI-H146 SCLC cell line, which expresses only SCF, was transfected with a c-kit expression vector. Kit protein immunoprecipitated from the transfected cells had a constitutive level of tyrosine phosphorylation, and these cells grew more vigorously in serum-free medium compared to control-transfected cells. This growth advantage could be blocked by the addition of the tyrosine kinase inhibitor herbimycin A. Growth of the c-kit-transfected cells could be further enhanced by the addition of bombesin or insulin-like growth factor-1, suggesting that the SCF/c-kit autocrine loop could function co-operatively with other SCLC autocrine loops. To further investigate the importance of this autocrine loop, a cell line that naturally coexpresses SCF and c-kit was transfected with a kinase-defective c-kit gene. Cells transfected with the defective gene showed a marked decrease in their ability to grow under growth factor-free conditions compared to cells transfected with the empty expression vector. Taken together, these studies demonstrate that the coexpression of the stem cell factor and c-kit genes is a major contributor to the growth factor independence of SCLC.
1 This work was supported by a Merit Review Award from the Department of Veterans Affairs (to G. W. K.).
2 To whom requests for reprints should be addressed, at McGuire Veterans Affairs Medical Center (111K), 1201 Broad Rock Boulevard, Richmond, VA 23249.
Received 7/19/95. Accepted 11/13/95.
This article has been cited by other articles:
|
|
 |
|
  H. Bougherara, F. Subra, R. Crepin, P. Tauc, C. Auclair, and M.-A. Poul The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment Mol. Cancer Res., September 1, 2009; 7(9): 1525 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-B. Han, H. Ren, H. Zhao, Y. Chi, K. Chen, B. Zhou, Y.-j. Liu, L. Zhang, B. Xu, B. Liu, et al. Hypoxia-inducible factor (HIF)-1{alpha} directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF) Carcinogenesis, October 1, 2008; 29(10): 1853 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Alam, J Fujimoto, I Jahan, E Sato, and T Tamaya Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers Ann. Onc., March 1, 2007; 18(3): 485 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Katiyar, X. Jiao, E. Wagner, M. P. Lisanti, and R. G. Pestell Somatic Excision Demonstrates that c-Jun Induces Cellular Migration and Invasion through Induction of Stem Cell Factor Mol. Cell. Biol., February 15, 2007; 27(4): 1356 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rehfeld, H. Geddert, A. Atamna, H. E. Gabbert, U. Steidl, R. Fenk, R. Kronenwett, R. Haas, and U.-P. Rohr Coexpression of Fragile Histidine Triad and c-kit Is Relevant for Prediction of Survival in Patients with Small Cell Lung Cancer. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2232 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Sambol, G. Ambrosini, R. C. Geha, P. T. Kennealey, P. DeCarolis, R. O'Connor, Y. V. Wu, M. Motwani, J.-H. Chen, G. K. Schwartz, et al. Flavopiridol Targets c-KIT Transcription and Induces Apoptosis in Gastrointestinal Stromal Tumor Cells Cancer Res., June 1, 2006; 66(11): 5858 - 5866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Garton, A. P.A. Crew, M. Franklin, A. R. Cooke, G. M. Wynne, L. Castaldo, J. Kahler, S. L. Winski, A. Franks, E. N. Brown, et al. OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models Cancer Res., January 15, 2006; 66(2): 1015 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann. Onc., November 1, 2005; 16(11): 1811 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tsurutani, K. A. West, J. Sayyah, J. J. Gills, and P. A. Dennis Inhibition of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway but not the MEK/ERK Pathway Attenuates Laminin-Mediated Small Cell Lung Cancer Cellular Survival and Resistance to Imatinib Mesylate or Chemotherapy Cancer Res., September 15, 2005; 65(18): 8423 - 8432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Meuwissen and A. Berns Mouse models for human lung cancer Genes & Dev., March 15, 2005; 19(6): 643 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G. W. Krystal The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy Clin. Cancer Res., February 15, 2005; 11(4): 1563 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tamborini, L. Bonadiman, T. Negri, A. Greco, S. Staurengo, P. Bidoli, U. Pastorino, M. A. Pierotti, and S. Pilotti Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8214 - 8219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gambacorti-Passerini, R. Piazza, L. Tornaghi, S. Pilotti, and E. Pogliani Development of c-Kit-expressing Small-Cell Lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment J Natl Cancer Inst, November 17, 2004; 96(22): 1723 - 1724. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lefevre, A.-L. Glotin, A. Calipel, F. Mouriaux, T. Tran, Z. Kherrouche, C.-A. Maurage, C. Auclair, and F. Mascarelli Roles of Stem Cell Factor/c-Kit and Effects of Glivec(R)/STI571 in Human Uveal Melanoma Cell Tumorigenesis J. Biol. Chem., July 23, 2004; 279(30): 31769 - 31779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. All-Ericsson, L. Girnita, A. Muller-Brunotte, B. Brodin, S. Seregard, A. Ostman, and O. Larsson c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target? Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2075 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kindler, F. Breitenbuecher, A. Marx, J. Beck, G. Hess, B. Weinkauf, J. Duyster, C. Peschel, C. J. Kirkpatrick, M. Theobald, et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia Blood, May 15, 2004; 103(10): 3644 - 3654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Raspollini, G. Amunni, A. Villanucci, G. Baroni, A. Taddei, and G. L. Taddei c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study Ann. Onc., April 1, 2004; 15(4): 594 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Johnson, T. Fischer, B. Fischer, D. Dunlop, D. Rischin, S. Silberman, M. O. Kowalski, D. Sayles, S. Dimitrijevic, C. Fletcher, et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5880 - 5887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Potti, N. Moazzam, K. Ramar, D. S. Hanekom, S. Kargas, and M. Koch CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma Ann. Onc., June 1, 2003; 14(6): 894 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Blackhall, M. Pintilie, M. Michael, N. Leighl, R. Feld, M.-S. Tsao, and F. A. Shepherd Expression and Prognostic Significance of Kit, Protein Kinase B, and Mitogen-activated Protein Kinase in Patients with Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2241 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Scotlandi, M. C. Manara, R. Strammiello, L. Landuzzi, S. Benini, S. Perdichizzi, M. Serra, A. Astolfi, G. Nicoletti, P.-L. Lollini, et al. c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions J. Clin. Oncol., May 15, 2003; 21(10): 1952 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Abrams, L. B. Lee, L. J. Murray, N. K. Pryer, and J. M. Cherrington SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor {beta} in Preclinical Models of Human Small Cell Lung Cancer Mol. Cancer Ther., May 1, 2003; 2(5): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tatton, G. M. Morley, R. Chopra, and A. Khwaja The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases J. Biol. Chem., February 7, 2003; 278(7): 4847 - 4853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Ronnstrand, A. Blaukat, K. M. Beeh, F. Oesch, B. Fischer, R. Buhl, et al. Characterization of c-kit Expression in Small Cell Lung Cancer: Prognostic and Therapeutic Implications Clin. Cancer Res., January 1, 2003; 9(1): 188 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kijima, G. Maulik, P. C. Ma, E. V. Tibaldi, R. E. Turner, B. Rollins, M. Sattler, B. E. Johnson, and R. Salgia Regulation of Cellular Proliferation, Cytoskeletal Function, and Signal Transduction through CXCR4 and c-Kit in Small Cell Lung Cancer Cells Cancer Res., November 1, 2002; 62(21): 6304 - 6311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Frost, P. T. Ferrao, T. P. Hughes, and L. K. Ashman Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant Mol. Cancer Ther., October 1, 2002; 1(12): 1115 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Krystal, G. Sulanke, and J. Litz Inhibition of Phosphatidylinositol 3-Kinase-Akt Signaling Blocks Growth, Promotes Apoptosis, and Enhances Sensitivity of Small Cell Lung Cancer Cells to Chemotherapy Mol. Cancer Ther., September 1, 2002; 1(11): 913 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maddens, A. Charruyer, I. Plo, P. Dubreuil, S. Berger, B. Salles, G. Laurent, and J.-P. Jaffrezou Kit signaling inhibits the sphingomyelin-ceramide pathway through PLCgamma 1: implication in stem cell factor radioprotective effect Blood, July 30, 2002; 100(4): 1294 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Moses, M. A. Jarvis, C. Raggo, Y. C. Bell, R. Ruhl, B. G. M. Luukkonen, D. J. Griffith, C. L. Wait, B. J. Druker, M. C. Heinrich, et al. Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kit Proto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial Cells J. Virol., July 17, 2002; 76(16): 8383 - 8399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. McDoniels-Silvers, C. F. Nimri, G. D. Stoner, R. A. Lubet, and M. You Differential Gene Expression in Human Lung Adenocarcinomas and Squamous Cell Carcinomas Clin. Cancer Res., April 1, 2002; 8(4): 1127 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Scappini, F. Onida, H. M. Kantarjian, L. Dong, S. Verstovsek, M. J. Keating, and M. Beran Effects of Signal Transduction Inhibitor 571 in Acute Myelogenous Leukemia Cells Clin. Cancer Res., December 1, 2001; 7(12): 3884 - 3893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Caceres-Cortes, J. A. Alvarado-Moreno, K. Waga, R. Rangel-Corona, A. Monroy-Garcia, L. Rocha-Zavaleta, J. Urdiales-Ramos, B. Weiss-Steider, A. Haman, P. Hugo, et al. Implication of Tyrosine Kinase Receptor and Steel Factor in Cell Density-dependent Growth in Cervical Cancers and Leukemias Cancer Res., August 1, 2001; 61(16): 6281 - 6289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O'Laughlin-Bunner, N. Radosevic, M. L. Taylor, Shivakrupa, C. DeBerry, D. D. Metcalfe, M. Zhou, C. Lowell, and D. Linnekin Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells Blood, July 15, 2001; 98(2): 343 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Krystal, S. Honsawek, D. Kiewlich, C. Liang, S. Vasile, L. Sun, G. McMahon, and K. E. Lipson Indolinone Tyrosine Kinase Inhibitors Block Kit Activation and Growth of Small Cell Lung Cancer Cells Cancer Res., May 1, 2001; 61(9): 3660 - 3668. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Landuzzi, C. De Giovanni, G. Nicoletti, I. Rossi, C. Ricci, A. Astolfi, L. Scopece, K. Scotlandi, M. Serra, G. P. Bagnara, et al. The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit Am. J. Pathol., December 1, 2000; 157(6): 2123 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Buchdunger, C. L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B. J. Druker, and N. B. Lydon Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 139 - 145. [Abstract] [Full Text]
|
|
|
|
|
|
G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth Clin. Cancer Res., August 1, 2000; 6(8): 3319 - 3326. [Abstract] [Full Text]
|
|
|
|
|
|
M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood, August 1, 2000; 96(3): 925 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bondzi, J. Litz, P. Dent, and G. W. Krystal Src Family Kinase Activity Is Required for Kit-mediated Mitogen-activated Protein (MAP) Kinase Activation, However Loss of Functional Retinoblastoma Protein Makes MAP Kinase Activation Unnecessary for Growth of Small Cell Lung Cancer Cells Cell Growth Differ., June 1, 2000; 11(6): 305 - 314. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Parrott, G. Kim, and M. K. Skinner Expression and Action of Kit Ligand/Stem Cell Factor in Normal Human and Bovine Ovarian Surface Epithelium and Ovarian Cancer Biol Reprod, June 1, 2000; 62(6): 1600 - 1609. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Tian, H. F. Frierson Jr., G. W. Krystal, and C. A. Moskaluk Activating c-kit Gene Mutations in Human Germ Cell Tumors Am. J. Pathol., June 1, 1999; 154(6): 1643 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. X. Tang, G. M. Brodeur, B. G. Campling, and N. Ikegaki Coexpression of Transcripts Encoding EPHB Receptor Protein Tyrosine Kinases and Their Ephrin-B Ligands in Human Small Cell Lung Carcinoma Clin. Cancer Res., February 1, 1999; 5(2): 455 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Leslie, J. O'Prey, C. Bartholomew, and P. R. Harrison An Activating Mutation in the Kit Receptor Abolishes the Stroma Requirement for Growth of ELM Erythroleukemia Cells, But Does Not Prevent Their Differentiation in Response to Erythropoietin Blood, December 15, 1998; 92(12): 4798 - 4807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Park, H. K. Plummer III, and G. W. Krystal Selective Sp1 Binding Is Critical for Maximal Activity of the Human c-kit Promoter Blood, December 1, 1998; 92(11): 4138 - 4149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ricotti, F. Fagioli, E. Garelli, C. Linari, N. Crescenzio, A. L. Horenstein, P. Pistamiglio, S. Vai, M. Berger, L. C. diMontezemolo, et al. c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells Blood, April 1, 1998; 91(7): 2397 - 2405. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
